Altre lingue AIM ImmunoTech Inc.

Azioni

AIM

US00901B1052

Tempo differito Nyse Altri mercati azionari 17:23:34 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,411 ^USD	+1,11%		-11,61%	-6,57%

10/04	AIM Immunotech annuncia dati intermedi positivi di prima linea, previsti dal protocollo, dallo studio di Ampligen combinato con Pembrolizumab per il trattamento del carcinoma ovarico ricorrente	CI
02/04	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	18/04
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	15/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	11/04
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
Challenges To Advance Notice Bylaws Are Spiking	08/04
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	28/03
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	26/03
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	26/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/03
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	25/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	22/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	20/03
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	20/03
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	15/03
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	15/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue AIM ImmunoTech Inc.

Azioni

AIM

US00901B1052

Altre lingue

Filtri